Eli Lilly and Co.’s blockbuster weight-loss and diabetes drugs are no longer considered to be in shortage in the US, ...
The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell ...
In contrast to Wave, Sarepta already has several therapies for DMD on the market, which is how it brought in trailing-12-month net income of slightly more than $47 million. It also has a few more ...
The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in expanding ...
Accusations of price gouging have been levied at the big grocery chains, which are the face of rising food prices. A report ...
The antibody-drug conjugate will be reviewed for the potential treatment of previously treated, unresectable or metastatic ...
Dr. David Minkoff, a high-ranking Scientologist, is accused by Whitney Mills’ family of depriving her of psychiatric ...
The U.S. Food and Drug Administration removed Eli Lilly's blockbuster weight-loss and diabetes drugs from its shortage list ...
The FDA declared the end to shortages of Zepbound and Mounjaro. That could mean new restrictions on pharmacies making ...
In Southeast Asia, people for centuries have chewed the leaves of the kratom tree — part of the coffee family — as a ...
Wellvii announced that it entered into a strategic partnership with B-Secur to combine at-home monitoring technology and ...
The U.S. Food and Drug Administration said Eli Lilly's diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are no longer in shortage, signaling that the company has succeeded in expanding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback